Celsion Corporation (NASDAQ:CLSN)’s share price gapped up prior to trading on Monday . The stock had previously closed at $3.06, but opened at $3.13. Celsion shares last traded at $3.26, with a volume of 3431800 shares.

A number of brokerages recently commented on CLSN. Maxim Group reaffirmed a “hold” rating on shares of Celsion in a report on Tuesday, August 15th. ValuEngine raised Celsion from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Oppenheimer Holdings, Inc. began coverage on Celsion in a report on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 target price on the stock. Finally, Zacks Investment Research cut Celsion from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $11.90.

An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC purchased a new stake in shares of Celsion Corporation (NASDAQ:CLSN) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned 1.30% of Celsion as of its most recent SEC filing. 6.41% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Celsion Corporation (CLSN) Shares Gap Up to $3.13” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/celsion-corporation-clsn-shares-gap-up-to-3-13/1729744.html.

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.